What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings

Wall Street analysts expect Glaukos (GKOS) to post quarterly loss of $0.43 per share in its upcoming report, which indicates a year-over-year increase of 31.8%. Revenues are expected to be $100.75 million, up 22.3% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.Given this perspective, it's time to examine the average forecasts of specific Glaukos metrics that are routinely monitored and predicted by Wall Street analysts.Analysts' assessment points toward 'Revenues- Corneal Health' reaching $21.53 million. The estimate indicates a change of -1.2% from the prior-year quarter.According to the collective judgment of analysts, 'Revenues- Glaucoma' should come in at $79.53 million. The estimate indicates a change of +31.3% from the prior-year quarter.The average prediction of analysts places 'Revenues- Glaucoma- United States' at $54.32 million. The estimate indicates a year-over-year change of +40.3%.The consensus estimate for 'Revenues- Corneal Health- United States' stands at $19.10 million. The estimate indicates a year-over-year change of -3%.Analysts predict that the 'Revenues- International' will reach $27.40 million. The estimate suggests a change of +14.3% year over year.It is projected by analysts that the 'Revenues- United States' will reach $73.43 million. The estimate points to a change of +25.7% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Revenues- Glaucoma- International' of $25.05 million. The estimate points to a change of +14.6% from the year-ago quarter.View all Key Company Metrics for Glaukos here>>>Glaukos shares have witnessed a change of -2% in the past month, in contrast to the Zacks S&P 500 composite's +4.7% move. With a Zacks Rank #3 (Hold), GKOS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Glaukos Corporation (GKOS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks